BMS’s Opdivo On Track For Esophageal Cancer Indication
Categories
Opdivo showed a 23% fall in the risk of death and 2.5-month improvement in median overall survival compared to chemotherapy in Phase III esophageal cancer trial.
https://scrip.pharmaintelligence.informa.com/SC125951/BMSs-Opdivo-On-Track-For-Esophageal-Cancer-Indication